Immune Signatures Identify Patient Subsets Deriving Long‐Term Benefit From First‐Line Rituximab in Follicular Lymphoma

Authors

Institutions

Publication Details

Journal
eJHaem
Published
2025-02-01
DOI
https://doi.org/10.1002/jha2.1103
Citations
1
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.47

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Immune Signatures Identify Patient Subsets Deriving Long‐Term Benefit From First‐Line Rituximab in Follicular Lymphoma

Enrico Derenzini, Alessandro Davini, Anna Vanazzi, Federica Melle et al.
1 citations
eJHaem
Lymphoma Diagnosis and Treatment
1.47
article

Immune Signatures Identify Patient Subsets Deriving Long‐Term Benefit From First‐Line Rituximab in Follicular Lymphoma

Enrico Derenzini, Alessandro Davini, Anna Vanazzi, Federica Melle, Giovanna Motta, Roberto Chiarle, Marta Castelli, Paulina Maria Nierychlewska, Maria Chiara Quattrocchi, Marcello Del Corvo, Alessio Maria Edoardo Maraglino, Valentina Tabanelli, Corrado Tarella, Angelica Calleri, Maria Rosaria Sapienza, Stefano Pileri, Ginevra Lolli
article en
1 citations

Abstract

No abstract available for this paper.
eJHaemVol. 6(1)
Boston Children's Hospital (US), University of Milan (IT), Azienda USL di Bologna (IT), University of Turin (IT), European Institute of Oncology (IT)
Associazione Italiana per la Ricerca sul Cancro
Good health and well-being
Openalex Percentile: Top 23%
Lymphoma Diagnosis and Treatment
1.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.